Oxford Endovascular secures £8M for aneurysm treatment

Oxford Endovascular, a spinout from the prestigious Oxford University, has successfully secured £8 million in a Series A funding round to propel the advancement of its cutting-edge brain aneurysm technology.

This significant financial backing not only underscores the potential and promise of Oxford Endovascular's innovative medical solution but also highlights the confidence and support from investors in the company's mission and capabilities.With the infusion of £8 million in funding, Oxford Endovascular is poised to accelerate the development and refinement of its brain aneurysm technology, paving the way for potential breakthroughs in the treatment of this critical medical condition.

The company's commitment to conducting human trials in the near future signifies a crucial step towards validating the efficacy and safety of its technology, ultimately bringing it closer to commercialization and widespread clinical adoption.As Oxford Endovascular embarks on this next phase of growth and innovation, the successful fundraising of £8 million not only provides the financial resources necessary for the company's research and development efforts but also positions it for significant strides in advancing the field of neurovascular healthcare.

By leveraging the expertise and resources of Oxford University, Oxford Endovascular is well-positioned to make a meaningful impact in the treatment of brain aneurysms, potentially transforming patient outcomes and revolutionizing the standard of care in this critical area of medicine.Founded in 2015, the medtech startup Oxford Endovascular aims to decrease the occurrence of brain hemorrhage by addressing intracranial aneurysms.

Their innovative device, OXIFLOW, is designed to redirect blood flow away from at-risk intracranial aneurysms, potentially preventing ruptures. The capital raised will be allocated towards advancing product development efforts, with a focus on preparing for clinical studies to validate the effectiveness and safety of their technology. This strategic use of funding underscores Oxford Endovascular's commitment to advancing medical innovation and improving outcomes for patients at risk of intracranial aneurysms.

OXIFLOW is a flow-diverter stent specifically designed for the treatment of intracranial aneurysms that are at risk of rupture. This miniature device is crafted using Nitinol, an advanced nickel titanium alloy known for its exceptional memory and design capabilities. The precision laser-cutting of the stent from Nitinol underscores the commitment to quality and innovation in the development of this critical medical technology.

OXIFLOW, unlike traditional flow-diverters, boasts a unique construction that enables more precise and reliable positioning and opening, as highlighted by the startup. This innovative design allows the device to conform more accurately to the patient's blood vessels, thereby reducing the likelihood of complications associated with current treatment methods. According to the startup, up to 35% of current device placements used in the treatment of brain aneurysms may result in complications that could potentially lead to adverse events.

The advanced technology and tailored design of OXIFLOW aim to address these challenges and enhance patient outcomes in the management of intracranial aneurysms.,CEO Mike Karim expressed, "With the backing of our investment partners, we are on the brink of realizing our goal of revolutionizing brain aneurysm treatment.

As we near the First-In-Human trials, our dedicated team is actively collaborating with regulators, healthcare professionals, and industry specialists to bring this innovative product to market. Our collective efforts aim to address a condition that impacts numerous individuals in the UK and globally, underscoring our commitment to advancing healthcare solutions and improving patient outcomes."

Oxford Endovascular has garnered financial support through grants from Horizon Europe, the European Union's primary funding program for research and innovation, as well as from Innovate UK, the United Kingdom's national innovation agency. Additionally, the company has been chosen by the EU for inclusion in its EIT-funded Covid rescue program. These funding sources underscore the recognition and support for Oxford Endovascular's innovative approach to addressing brain aneurysms and advancing medical technology.